Nejm Resident 360 - Curbside Consults Podcast

The COVID-19 pandemic has forced innovation in health care in many ways, one of which is putting to test advances in digital health. There has been no better time to test its value than in this environment of social distancing, reduced contact, and heightened health...

In this episode of Curbside Consults: Statistical Review, we explore the interpretation of secondary outcomes in clinical trials using the following two articles recently published in NEJM: Bonaca MP et al. Rivaroxaban in Peripheral Artery Disease after Revascularization...

In today’s podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of low-dose rivaroxaban in peripheral artery disease after revascularization.

In this episode of Curbside Consults, we continue our exploration of the prescription and use of opioids in the treatment of chronic pain. We hear a patient’s point of view, exploring how a patient with chronic pain manages his relationship with his provider, pharmacy, and...

In this statistical review episode of Curbside Consults, we explore descriptive epidemiology studies of the COVID-19 outbreak using an article by Guan and colleagues published online in NEJM on February 28, 2020. To help explain the approach to outbreak study analysis...

Managing patients with chronic pain is a constant challenge for physicians. We frequently receive questions from clinicians about handling these complex situations. Questions about prescribing opioids include when to use opioids and how to monitor their use. In this...

In this special episode of Curbside Consults, this year’s NEJM Editorial Fellows discuss Quality Improvement (QI) in residency and the launch of the NEJM Resident 360 QI Challenge.

The winter peak in respiratory tract infections adds considerable pressure to pediatric emergency departments and intensive care units across the country. In this episode of Curbside Consults, Dr. Phoebe Yager, pediatric intensivist and Chief of the Division of...

Survival data are central to the analysis of clinical trials, with many journal club discussions anchored around the tables and graphs used to display these outcomes. In this episode of Curbside Consults, we are joined once again by Dr. David Harrington, statistical editor...

In the summer of 2019, the medical community was faced with a mysterious series of acute and severe lung illnesses linked to e-cigarette use. In this episode of Curbside Consults, Dr. John Brownstein, chief innovation officer at Boston Children’s Hospital, discusses how...

Together with Dr. David Harrington, 2018/2019 NEJM Editorial Fellows Angie, Angela, and Amanda summarize and wrap up the NEJM experience. 

Missing data are common in randomized, controlled trials. Why does this happen? How do we interpret these missing data? In this episode of Curbside Consults, Dr. David Harrington, statistical editor at the NEJM, joins us for a discussion on missing data and how to interpret missing data in studies.

Osteoporosis affects more than 10 million people living in the United States. Although a number of medications are available for treatment of osteoporosis, it remains undertreated. In this episode of Curbside Consults, Dr. Clifford J. Rosen, Professor of Medicine at Tufts University School of Medicine and Associate Editor at the NEJM, joins us to...

Although randomized controlled trials get much of the attention in journal club, observational studies allow researchers to ask questions that may not be possible with RCTs. In this episode of Curbside Consults, we discuss the strengths and limitations of large observational studies and how to critically appraise them.

In the current era of the opioid epidemic, what role do opioid prescriptions play? With all the scrutiny physicians face when prescribing opioids, what can trainees do to be safe and thoughtful prescribers? Dr. Scott Hadland, Assistant Professor of Pediatrics at Boston University School of Medicine and on the faculty of the Grayken Center for...

Clinical trials can be stopped early for a range of reasons. But when that happens, it can be tricky to interpret the results and to understand the reasons why the trial was stopped in the first place. Join us in this episode of Curbside Consults with Dr. David Harrington, statistical editor at the NEJM, as we discuss...

Intravenous thrombolysis has been an essential component in the management of acute ischemic stroke. Current guidelines recommend that thrombolysis be administered within 3 hours of the onset of first neurologic symptoms. However, two recent trials published in NEJM challenge this time paradigm. In this episode of Curbside Consults...

Practical or pragmatic trials are designed to show the effectiveness of an intervention in the complex clinical setting of daily practice. But what makes a trial pragmatic? Can a clinical trial ever be completely pragmatic? Join us in this episode of Curbside Consults with Dr. David Harrington, statistical editor at the NEJM, as we discuss the elements...

The rise in popularity of e-cigarettes in the last 5 years has changed the landscape and language surrounding nicotine delivery, smoking cessation, and adolescent substance use. In this episode of Curbside Consults, Dr. Jonathan Winickoff, Professor of Pediatrics at Mass General Hospital for Children and Director of Pediatric Research...

Composite outcomes are frequently used as primary outcomes in randomized-controlled trials and observational studies. Why are they used? What are the limitations of their use? How are composite outcomes interpreted? Join us in this episode as Dr. David Harrington, statistical editor at the NEJM, helps breakdown composite outcomes.